Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT01291342 |
| Other study ID # |
1702 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
February 5, 2011 |
| Last updated |
February 5, 2013 |
| Start date |
September 2011 |
| Est. completion date |
September 2012 |
Study information
| Verified date |
August 2012 |
| Source |
The Nazareth Hospital, Israel |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
Israel: Ministry of Health |
| Study type |
Observational
|
Clinical Trial Summary
Preeclampsia is a form of hypertension that is unique to human pregnancy. The incidence of
the disease ranges between 2 and 7 percent in healthy nulliparous women. The etiology of
preeclampsia is unknown.
Women with preeclampsia may exhibit a symptom complex ranging from minimal BP elevation to
derangements of multiple organ systems. The renal, hematologic, and hepatic systems are most
likely to be involved.
More than 100 clinical, biophysical, and biochemical tests have been recommended to predict
or identify the patient at risk for the future development of the disease.
The results of the pooled data for the various tests and the lack of agreement between
serial tests suggest that none of these clinical tests is sufficiently reliable for use as a
screening test in clinical practice. As a result there is obviously a great need to develop
a novel technology for the early detection of this pregnancy complication before its
clinical manifestations appear. An early detection can help in early treatment to prevent or
at least minimize the sequel of this disease.
The aim of this project is the early detection of "Preeclampsia" and other pregnancy
complications using volatile biomarkers appearing in exhaled breath and/or blood samples,
using a simple and inexpensive toll termed NA-NOSE.
Phase-I: The primary phase of this project is the comparison between volatile biomarkers'
patterns of pregnant women suffering from "Preeclampsia", pregnant women that are considered
to have "Normal Pregnancy", and healthy "Non-Pregnant" women.
Phase-II: The secondary phase of this project is the ability to predict "Preeclampsia", as
compared, head-to-head, with other potential predictors used in the current clinical
practice.
Description:
Preeclampsia is a form of hypertension that is unique to human pregnancy. The clinical
findings of preeclampsia can manifest as either a maternal syndrome (hypertension and
proteinuria with or without other multisystem abnormalities) or as a fetal syndrome (fetal
growth restriction, reduced amniotic fluid, and abnormal oxygenation).
The incidence of preeclampsia ranges between 2 and 7 percent in healthy nulliparous women.
In these women, preeclampsia is generally mild, with the onset near term or intrapartum (75
percent of cases), and the condition conveys only a minimally increased risk for adverse
pregnancy outcome. In contrast, the incidence and severity of preeclampsia are substantially
higher in women with multifetal gestation, chronic hypertension, previous preeclampsia,
pregestational diabetes mellitus, and in those with preexisting thrombophilias.
The etiology of preeclampsia is unknown. Many theories have been suggested, but most of them
have not withstood the test of time. Some of these theories: Abnormal trophoblast invasion,
coagulation abnormalities, vascular endothelial damage, cardiovascular maladaptation,
immunologic phenomena, genetic predisposition and dietary deficiencies or excesses.
Preeclampsia is a clinical syndrome that embraces a wide spectrum of signs and symptoms that
have been clinically observed to develop alone or in combination. The classic triad of
preeclampsia includes: hypertension, proteinuria, and edema. However, there is now universal
agreement that edema should not be considered as part of the diagnosis of preeclampsia. The
diagnosis of preeclampsia requires the presence of an elevated blood pressure (BP) with
proteinuria,3 usually starting after the 20th week of the pregnancy, but the severity of the
disease process is generally based on the maternal BP which is considered as the traditional
hallmark for diagnosis of the disease.
Women with preeclampsia may exhibit a symptom complex ranging from minimal BP elevation to
derangements of multiple organ systems. The renal, hematologic, and hepatic systems are most
likely to be involved.
Renal function is usually impaired in almost every case as proteinuria is always found. In
preeclampsia, vasospasm and glomerular capillary endothelial swelling (glomerular
endotheliosis) lead to an average reduction in GFR (glomerular filtration rate) of 25
percent below the rate for normal pregnancy. Serum creatinine is rarely elevated in
preeclampsia, but uric acid is commonly increased. Despite the fact that uric acid levels
are elevated in women with preeclampsia, this test is not sensitive or specific for the
diagnosis of the disease.
The liver is not primarily involved in preeclampsia, and hepatic involvement is observed in
only 10 percent of women with severe preeclampsia. Fibrin deposition has been found along
the walls of hepatic sinusoids in preeclamptic patients with no laboratory or histologic
evidence of liver involvement. When liver dysfunction does occur in preeclampsia, mild
elevation of serum transaminase is most common. Bilirubin is rarely increased in
preeclampsia, but when elevated, the indirect fraction predominates. Elevated liver enzymes
are part of the of HELLP syndrome, a variant of severe preeclampsia.
Thrombocytopenia is the most common hematologic abnormality in women with preeclampsia. It
is correlated with the severity of the disease process and the presence or absence of
placental abruption. A platelet count of less than 150,000/mm3 has been reported in 32 to 50
percent of women with severe preeclampsia, And in 15 percent of cases of women with
hypertension during pregnancy.
Review of the literature reveals that more than 100 clinical, biophysical, and biochemical
tests have been recommended to predict or identify the patient at risk for the future
development of the disease.
The results of the pooled data for the various tests and the lack of agreement between
serial tests suggest that none of these clinical tests is sufficiently reliable for use as a
screening test in clinical practice. As a result there is obviously a great need to develop
a novel technology for the early detection of this pregnancy complication before its
clinical manifestations appear. An early detection can help in early treatment to prevent or
at least minimize the sequel of this disease.
Volatile Biomarkers of Preeclampsia:
The intensity of oxidative stress in women having normal pregnancy, preeclampsia, and
nonpregnant women, as expressed by volatile biomarkers through exhaled breath, was studied
by GC-Chromatography/Mass-Spectrometry (GC-MS)by the group of Moretti and Phillips. A 3-D
display of abundance of C4-C20 alkanes and monomethylated alkanes showed that the mean
volume under curve was significantly higher in preeclampsia patients than in normal pregnant
women (P<003) and nonpregnant control subjects (P<005). A predictive model employing five
volatile biomarkers (undecane, 6-methyltridecane, 2-methylpentane, 5-methyltetradecane, and
2-methylnonane) distinguished preeclampsia from uncomplicated pregnancy (sensitivity=92.3%,
specificity=89.7%; cross-validated sensitivity=88.5%, specificity=79.3%). While promising,
the clinical value of this breath test as a predictor of preeclampsia is still unknown. This
could be attributed to the fact that the study focused only on the oxidative stress relation
to the preeclampsia at the time metabolic pathways cannot be ignored.
A support for the latter comes from the involvement of many disorders (e.g., renal,
hematologic, and hepatic), which has been found to emit volatile biomarkers, during the
preeclampsia.
Putting this preliminary study into wider perspective, longitudinal studies are required to
determine if increased breath biomarkers of oxidative stress, and, also, metabolic pathways
during earlier stages of pregnancy can predict the onset of preeclampsia. While part of the
required knowledge could be gained by means of mass-spectrometry techniques, the use of
these techniques are impeded by the need for expensive equipment, the high levels of
expertise required to operate such instruments, the speed required for sampling and
analysis, and the need for preconcentration techniques (a technique that allows detecting
only part (15-20%) of the volatile biomarkers found in the real exhaled breath).
For preeclampsia's volatile biomarker testing to become a clinical reality, several advances
in the knowledge of specific preeclampsia volatile biomarkers and sensor development need to
occur. Chemical sensor matrices, based on nanomaterials, are more likely to become a
clinical and laboratory diagnostic tool, because they are significantly smaller,
easier-to-use, and less expensive. An ideal chemical sensor for volatile biomarker analysis
should be sensitive at very low analyte concentrations in the presence of water vapour (as
breath samples contain 80-90% RH). Furthermore, it should respond rapidly and differently to
small changes in concentration, and provide a consistent output that is specific to a given
exposure.
Objectives:
The aim of this project is the early detection of "Preeclampsia" and other pregnancy
complications using volatile biomarkers appearing in exhaled breath and/or blood samples,
using a simple and inexpensive toll termed NA-NOSE.
Phase-I: The primary phase of this project is the comparison between volatile biomarkers'
patterns of pregnant women suffering from "Preeclampsia", pregnant women that are considered
to have "Normal Pregnancy", and healthy "Non-Pregnant" women.
Phase-II: The secondary phase of this project is the ability to predict "Preeclampsia", as
compared, head-to-head, with other potential predictors used in the current clinical
practice.
Methodology:
Study Design and Outline:
Phase-I of this study will concentrate on a cross sectional breath tests of three groups of
young women who agreed to participate and signed an informed consent form that was approved
by the institutional Helsinki committee in the Nazareth Hospital.
Groups:
- Preeclampsia: 30 preeclamptic pregnant women with gestational age >24 weeks and no
chronic medical disorders who are not in labor and their fetus is alive. Preeclampsia
is defined as blood pressure of >140/90 mm Hg on 2 separate occasions at least 4 hours
but not more than one week apart with proteinuria. Proteinuria is defined as a urinary
dipstick value >1+ (30mg/dL), or a 24 hour urine collection with a protein excretion of
>300mg.
- Uncomplicated pregnancy: 30 normotensive pregnant women with gestational age >24 weeks
and no chronic medical disorders who has no obstetrical problems, not in labor and
their fetus is alive.
- Healthy controls: 30 healthy non-pregnant control women recruited mainly from employees
of the Nazareth Hospital who are healthy, not on medications and has not delivered a
baby or conceived during the year before the breath collection.
Breath Test Sampling for the NA-NOSE as well as the blood samples will be done in the
Technion.
Chemical analysis:
The LNBD group (Technion) will determine the most pronounced electrical features for each
organically functionalized nanosensor in response to the volatile biomarkers (of both breath
and blood samples), and of the entire sensor array, using classical multi-linear regression
models and neural network models. Different linear and nonlinear algorithms will be sought
based on principal component analysis and chaotic parameters in order to reduce the
dimensions of the data, and to extract the most important information. The exhaled air will
also be analyzed by Gas-Chromatography/Mass-Spectrometry (GC-MS) in conjugation with thermal
desorption for determining the nature and composition of the volatile biomarkers in the
related breath and blood samples.
